Glycomine is a startup based in the United States, most recent round Series-c-plus, 3 tracked investors.
Glycomine is a startup founded in 2020 based in the United States. Its most recent tracked round is Series-c-plus. Brouky records 3 investors associated with the company.
Glycomine is a biotechnology company focused on developing replacement therapies for rare genetic diseases, specifically targeting phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG) with its lead candidate GLM101, a mannose-1-phosphate replacement therapy.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.